Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET A-PLCβ-PKCε pathway

Molecular and Cellular Endocrinology

Volumn 351, Issue 2, 2012, Pages 176-183

  Ho, Ping Chih ^a   Tsui, Yao Chen ^a   Lin, Yi Wei ^a   Persaud, Shawna D ^a   Wei, Li Na ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Ambrisentan; Cytoplasm; Endothelin 1; ET A receptor; Insulin sensitivity; RIP140

Indexed keywords

ADIPONECTIN; AMBRISENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; PHOSPHOLIPASE C BETA; PROTEIN KINASE C EPSILON; RECEPTOR INTERACTING PROTEIN 140;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BLOCKING; UPREGULATION;

3T3-L1 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; ENDOTHELIN-1; FATTY LIVER; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NUCLEAR PROTEINS; OBESITY; PHENYLPROPIONATES; PHOSPHOINOSITIDE PHOSPHOLIPASE C; PHOSPHOLIPASE C BETA; PYRIDAZINES; RECEPTOR, ENDOTHELIN A; RNA INTERFERENCE; RNA, SMALL CYTOPLASMIC;

EID: 84862812765     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.12.003     Document Type: Article

References (31)

1. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010, 121:2045-2066.
2. Bedi D., Clarke K.J., Dennis J.C., Zhong Q., Brunson B.L., Morrison E.E., Judd R.L. Endothelin-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5-bisphosphate/actin-dependent mechanism. Biochem. Biophys. Res. Commun. 2006, 345:332-339.
3. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 2008, 358:2148-2159.
4. Casserly B., Klinger J.R. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des. Dev. Ther. 2009, 2:265-280.
5. Chai S.P., Chang Y.N., Fong J.C. Endothelin-1 stimulates interleukin-6 secretion from 3T3-L1 adipocytes. Biochim. Biophys. Acta 2009, 1790:213-218.
6. Ellershaw D.C., Gurney A.M. Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br. J. Pharmacol. 2001, 134:621-631.
7. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9:367-377.
8. Gupta P., Ho P.C., Huq M.D., Khan A.A., Tsai N.P., Wei L.N. PKCepsilon stimulated arginine methylation of RIP140 for its nuclear-cytoplasmic export in adipocyte differentiation. PLoS One 2008, 3:e2658.
9. Herman M.A., Kahn B.B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 2006, 116:1767-1775.
10. Ho P.C., Gupta P., Tsui Y.C., Ha S.G., Huq M., Wei L.N. Modulation of lysine acetylation-stimulated repressive activity by Erk2-mediated phosphorylation of RIP140 in adipocyte differentiation. Cell. Signal. 2008, 20:1911-1919.
11. Ho P.C., Lin Y.W., Tsui Y.C., Gupta P., Wei L.N. A negative regulatory pathway of GLUT4 trafficking in adipocyte: new function of RIP140 in the cytoplasm via AS160. Cell Metab. 2009, 10:516-523.
12. Ho, P.C., Chuang, Y.S., Hung, C.H., Wei, L.N., 2011. Cytoplasmic receptor-interacting protein 140 (RIP140) interacts with perilipin to regulate lipolysis, Cell. Signal. 23, 1396-1403.
13. Ho P.C., Wei L.N. Negative regulation of adiponectin secretion by receptor interacting protein 140 (RIP140). Cell. Signal. 2012, 24:71-76.
14. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004, 351:1425-1436.
15. Huq M.D., Tsai N.P., Lin Y.P., Higgins L., Wei L.N. Vitamin B6 conjugation to nuclear corepressor RIP140 and its role in gene regulation. Nat. Chem. Biol. 2007, 3:161-165.
16. Ishibashi K., Imamura T., Sharma P.M., Ugi S., Olefsky J.M. The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes. Endocrinology 2000, 141:4623-4628.
17. Ishibashi K.I., Imamura T., Sharma P.M., Huang J., Ugi S., Olefsky J.M. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J. Clin. Invest. 2001, 107:1193-1202.
18. Leonardsson G., Steel J.H., Christian M., Pocock V., Milligan S., Bell J., So P.W., Medina-Gomez G., Vidal-Puig A., White R., Parker M.G. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl. Acad. Sci. USA 2004, 101:8437-8442.
19. Marasciulo F.L., Montagnani M., Potenza M.A. Endothelin-1: the yin and yang on vascular function. Curr. Med. Chem. 2006, 13:1655-1665.
20. Mostaqul Huq M.D., Gupta P., Wei L.N. Post-translational modifications of nuclear co-repressor RIP140: a therapeutic target for metabolic diseases. Curr. Med. Chem. 2008, 15:386-392.
21. Mostaqul Huq M.D., Gupta P., Tsai N.P., White R., Parker M.G., Wei L.N. Suppression of receptor interacting protein 140 repressive activity by protein arginine methylation. EMBO J. 2006, 25:5094-5104.
22. O'Carroll S.J., Mitchell M.D., Faenza I., Cocco L., Gilmour R.S. Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. Cell. Signal. 2009, 21:926-935.
23. Potenza M.A., Gagliardi S., Nacci C., Carratu M.R., Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr. Med. Chem. 2009, 16:94-112.
24. Powelka A.M., Seth A., Virbasius J.V., Kiskinis E., Nicoloro S.M., Guilherme A., Tang X., Straubhaar J., Cherniack A.D., Parker M.G., Czech M.P. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J. Clin. Invest. 2006, 116:125-136.
25. Rehsia N.S., Dhalla N.S. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail. Rev. 2010, 15:85-101.
26. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 2008, 118:2992-3002.
27. Schneider J.G., Tilly N., Hierl T., Sommer U., Hamann A., Dugi K., Leidig-Bruckner G., Kasperk C. Elevated plasma endothelin-1 levels in diabetes mellitus. Am. J. Hypertens. 2002, 15:967-972.
28. Shetty N., Derk C.T. Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm. Allergy Drug Targets 2011, 10:19-26.
29. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
30. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
31. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.